Why Changing Marijuana's DEA Categorization Could Be 'The Most Consequential Action Out Of DC'

In a recent interview at the Benzinga Cannabis Capital Conference in Miami, Kris Krane, cannabis industry consultant and director of cannabis development for KCSA Strategic Communications, stressed the crucial focus on the presidential administration this year.

The founder of 4Front Ventures Corp. FFNT FFNTF called for a thorough scheduling review of marijuana, stating, "That has the potential to be the most consequential action that's come out of DC on the issue of cannabis possibly ever."

Krane also urged President Joe Biden, the U.S. Food and Drug Administration (FDA) and other relevant agencies to conduct a positive evaluation, ideally leading to de-scheduling marijuana from the Controlled Substances Act. He also suggested considering alternative schedules, such as Schedule 3, 4, or 5. “We need everybody pushing as hard as they can on the administration and [Washington] DC, to get this done (...) If we can get it done before the end of this administration it’s a game-changer for the industry.”

According to him, this effort is vital, but it all starts at the state level. While the administration's actions are crucial, the foundation for cannabis reform lies within individual states, where the industry's growth and progress can truly take shape.

The upcoming Benzinga Cannabis Capital Conference, returning to Chicago on September 27 and 28, aims to further discussions and insights into the cannabis industry's future. As the industry eagerly awaits potential regulatory changes at the federal level, this event provides a platform for experts and enthusiasts alike to gather, share ideas, and explore opportunities. All relevant information is available on bzcannabis.com

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!